Currently in the development phase, Cellares’ automated platform will be suitable for producing CAR-T, hematopoietic stem cells (HSC), T-cell receptor (TCR), natural killer (NK), TIL (Tumor infiltrating lymphocytes), T-reg, and γδ T cells . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Cellares’ Automation Route for Cancer Cell Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.
